Months later, here he is, back in the Super Bowl AGAIN. And he had a message using one GIF for all the haters out there who bet against him or made fun of him or whatever. After jokingly ...

HAVING thoroughly enjoyed taking the Ford Puma ST for a spin back in 2023, Drive thought it was high time that we also checked out the lukewarm version of Ford’s best-selling crossover SUV.

For nearly a decade, Eli Lilly has been operating a global capability center (GCC) in Bengaluru, India. Now, with its business booming, the company is setting up a similar site 10 hours to the ...

For Mustang enthusiasts, life just got a little sweeter. Ford Motor Co. is offering the first special edition of its Mustang GTD — the high-performance, street-legal supercar the company started ...

Eli Lilly is reenergizing its attempt to challenge Novartis and Roche for a breast cancer market, kicking off the J.P. Morgan Healthcare Conference with a deal to buy Scorpion Therapeutics ...

"Heard it here first… @ford x @redbullracing," he captioned it. Earlier, Red Bull team principal Christian Horner acknowledged the challenges associated with the dream project. The competition ...

Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF) market, offering Mediar Therapeutics $99 million in upfront and near-term payments for global rights to an asset that is ...

Ricks, Lilly chair and CEO. "The rest of our medicines performed within our expectations." "2024 was a pivotal and highly successful year for Lilly, and we expect to continue our momentum in 2025 ...

Eli Lilly & Co.’s fourth-quarter revenue fell short of analysts’ estimates as the drugmaker struggled to forecast demand for its popular weight-loss and diabetes shots for the second quarter ...

Eli Lilly spooked the market with warnings of a small revenue slowdown in Q4 2024. Lilly nevertheless delivered good news about its prospects for sales growth in 2025. The company also dropped a ...

The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3Kα inhibitor currently in a Phase 1/2 clinical trial STX ...

Eli Lilly (NYSE:LLY) is in advanced discussions to purchase cancer-focused biotech Scorpion Therapeutics for as much as $2.5 billion. A deal is likely to be reached in the coming days ahead of the ...